Aug 2026· ACS Applied Materials and Interfaces· 0 citations· 57 references
Medicine
TL;DR
This hydrogel-nanoparticle composite platform helps overcome photothermal therapy-induced immune suppression, reduce oxidative stress in the TME, and inhibit tumor metastasis, offering a promising strategy for enhancing cancer immunotherapy.
Abstract
Photothermal therapy can induce local tumor cell death and trigger antitumor immune responses. However, its efficacy is often limited by insufficient lymph node immune priming and by sustained ROS generated from thermal stress, which suppress immune cell function. An oxidative-stress-responsive injectable hydrogel-nanoparticle composite (TP@PPM) was constructed by embedding MSA-2-loaded PEGylated polydopamine nanoparticles (PPM) into a TSPBA-PVA hydrogel. Upon near-infrared (NIR) irradiation, PPM mediated photothermal cytotoxicity, induced tumor-cell thermal stress and mitochondrial dysfunction, and generated reactive oxygen species (ROS), triggering immunogenic cell death. The relatively stable and diffusible H2O2 generated within the tumor microenvironment can enter the tumor interstitium and oxidize boronate ester crosslinks in the hydrogel, thereby promoting hydrogel degradation and enabling controlled PPM release. Then, the PPM accumulated in tumor-draining lymph nodes within 6 h and delivered MSA-2 to dendritic cells and activated the STING pathway. In vitro, TP@PPM attenuated MDSC-associated ROS accumulation and restored T cell proliferation to 44.8% in an MDSC-T cell coculture system. In vivo, TP@PPM combined with NIR irradiation promoted the infiltration of CD8+/CD4+ T cell and reduced pulmonary metastasis of the tumor. This hydrogel-nanoparticle composite platform helps overcome photothermal therapy-induced immune suppression, reduce oxidative stress in the TME, and inhibit tumor metastasis, offering a promising strategy for enhancing cancer immunotherapy.
A TME-adaptive platform that couples photothermal therapy with spatially confined STING activation is established, offering a mechanistically grounded strategy to overcome immune resistance in osteosarcoma.
Zhao-Long Yu, Qiu-Qun Xiao, Zhongyi Sun et al.· Photodiagnosis and Photodyna...· 0 citations
Cancer immunotherapy exhibits limited efficacy in immunologically "cold" tumors due to insufficient T-cell infiltration and immunosuppressive tumor microenvironment. The efficacy of photodynamic therapy (PDT) is restricted by inadequate tumor-specific aggregation of photosensitizers and therapeutic resistance regulated...
PANoptosis, an inflammatory cell death integrating pyroptosis, apoptosis, and necroptosis, has emerged as a promising approach for tumor immunotherapy. Reactive oxygen species (ROS) generation is the predominant strategy for triggering PANoptosis. However, in solid tumors, the hypoxic microenvironment suppresses ROS pr...
Kexin Wen, Chenxi Zhang, Qin Fan et al.· Journal of Controlled Releas...· 0 citations
ABSTRACT Postoperative tumor recurrence remains a major challenge in solid tumor treatment, largely attributed to an immunosuppressive tumor microenvironment and the enrichment of extracellular glutathione (GSH) in the tumor bed, which supports tumor cell survival and proliferation. To address these issues, we designed...
Cong Jiang, Zi-Fan Yang, Rong Guo et al.· Advancement of science· 0 citations
Nanosecond pulsed electric field (nsPEF) ablation enables non-thermal tumor destruction with favorable tissue selectivity, but its long-term efficacy is often limited by postoperative recurrence. Here, we developed an electroporation-primed, tumor microenvironment-responsive core-shell cascade nanoparticle, ZnO2-NiFc@M...
Jia-Xin Zhao, Zhe-Yu Fang, Zi-Wei Luo et al.· Materials Today Bio· 0 citations
It is reported that horseradish peroxidase (HRP) can catalyze artemisinin to generate ROS, and a "ROS bomb" nanomedicine was designed for antitumor immunotherapy, offering a potent approach for treating deep-seated tumors.
Ke-Qiang Lu, Yaoquan Su, Xing-Chen Zhou et al.· Journal of Controlled Releas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.